The Schenk Lab studies the lung cancer tumor microenvironment, a diverse collection of cell types that can be found in and around lung tumors. Dr. Schenk is focused on the immune cells within the tumor and how specific sub-types can contribute to treatment resistance and ultimately hopes to use lab findings to improve therapy for patients with lung cancer.
Pacheco JM, Camidge DR, Doebele RC, Schenk E. A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer.” Front Oncol. 2019;9:195. Review
Kleczko EK, Kwak JW, Schenk EL, Nemenoff RA. “Targeting the Complement Pathway as a Therapeutic Strategy in Lung Cancer.” Front Immunol. 2019;10:954. Review
Bullock B, Kimball A, Poczobutt J, Li H, Kwak J, Neuwelt A, Johnson A, Kleczko E, Kaspar R, Wagner E, Hopp K, Schenk E, Weiser-Evans M, Clambey E, and Nemenoff R. “Tumor-Intrinsic Response to IFNg Shapes the Tumor Microenvironment and Anti-PD-1 Response in NSCLC" In press, Life Sci Alliance 2019 Jun;2(3).
Schenk EL, Mandrekar SJ, Dy GK, Aubry MC, Tan AD, Dakhil SR, Sachs BA, Nieva JJ, Bertino E, Lee Hann C, Schild SE, Wadsworth TW, Adjei AA, and Molina JR. “A randomized double-blind phase II study of the Seneca Valley Virus (NTX-010) vs placebo for patients with extensive stage SCLC (ES-SCLC) who were stable or responding after at least 4 cycles of platinum-based chemotherapy: NCCTG (Alliance) N0923 Study.” In press, Journal of Thoracic Oncology, October 2019.
Erin Schenk, MD, PhD
Kristi Zevin, MS